Peptides Academy
Cerebrolysin
EVER Neuro Pharma
Cerebrolysin is a multi-component neuropeptide preparation obtained by standardized enzymatic proteolysis of purified porcine brain proteins. The resulting mixture contains approximately 25% low-molecular-weight peptides (≤10 kDa) and 75% free amino acids. It has been used clinically since the 1970s, primarily in Europe and Asia, for acute ischemic stroke, traumatic brain injury, and vascular dementia. The preparation's neurotrophic profile mimics endogenous nerve growth factors — it has demonstrated BDNF-like and CNTF-like activity in vitro, promoting neuronal survival, dendritic arborization, and synaptic plasticity. Multiple randomized controlled trials (including the CASTA and CERE-LYSE trials) have evaluated Cerebrolysin in acute stroke, with mixed but generally favorable results on functional recovery at 90 days. It is not FDA-approved in the United States but holds marketing authorization in over 40 countries.
Specifications
| Origin / Manufacturer | Porcine brain-derived |
| Active Components | Neuropeptide mixture (≤10 kDa)Free amino acidsSodium chloride (isotonic solution) |
| Storage | Store at 2–25°C, protect from light |
| Shelf Life | 36 months |
| Form Factor | Injectable solution (1 mL, 5 mL, 10 mL, 20 mL ampoules) |
Clinical Evidence
Clinical report reference
Clinical report reference
Clinical report reference
Frequently Asked Questions
Sources & References
Every clinical claim on this page traces to a primary peer-reviewed source.
- 1Heiss WD, Brainin M, Bornstein NM, et al.. Cerebrolysin in Patients With Acute Ischemic Stroke in Asia (CASTA). Stroke. 2012;43(3):630-636. PMID:22246690
- 2Chen N, Yang M, Guo J, et al.. Cerebrolysin for vascular dementia. Cochrane Database of Systematic Reviews. 2013(1). doi:10.1002/14651858.CD008900.pub2 PMID:23440835
- 3Bornstein NM, Guekht A, Vester J, et al.. Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of five large-scale clinical trials. Journal of Neural Transmission. 2018;125(10):1567-1574. doi:10.1007/s00702-018-1892-9 PMID:29943156
Reviewed by
Clinical Research Review Board
Neurology & Pharmacology Review
All clinical claims cross-checked against primary sources. Read our editorial policy →
Related Peptides
Dihexa
Research-Grade
A hexapeptide analog of angiotensin IV that crosses the blood-brain barrier and promotes synaptogenesis via hepatocyte growth factor (HGF) signaling — studied for cognitive enhancement and neurodegenerative disease.
Selank
Research-Grade
A synthetic heptapeptide analog of tuftsin, developed at the Russian Institute of Molecular Genetics as an anxiolytic nootropic administered intranasally.
Semax
Research-Grade
A synthetic heptapeptide fragment of ACTH (4-10) developed in Russia as a cognitive enhancer, used clinically there for stroke recovery and anxiety.